XIST and non-small cell lung carcinoma: After verification of XIST overexpression in clinical NSCLC samples, especially DDP-treated specimens, as well as in human NSCLC cell lines, we conducted gain- and loss-of-function studies and co-expression analyses to identify XIST’s binding partners and further elucidate its oncogenic effect.